Keay Nakae

Stock Analyst at Chardan Capital

(1.25)
# 1848
Out of 5,352 analysts
278
Total ratings
31.96%
Success rate
8.51%
Average return
39 Stocks
Name Action PT Current % Upside Ratings Updated
SABS SAB Biotherapeutics
Maintains: Buy
20 20
1.86 975.27% 15 May 15, 2025
OBIO Orchestra BioMed Hld...
Maintains: Buy
20 20
3.25 515.38% 10 May 13, 2025
KRRO Korro Bio
Maintains: Buy
25 25
11.95 109.21% 2 May 13, 2025
COYA Coya Therapeutics
Maintains: Buy
14 14
5.71 145.18% 18 May 13, 2025
ARWR Arrowhead Pharma
Maintains: Buy
60 60
16.61 261.23% 19 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
50 50
13.27 276.79% 11 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
65 65
34.43 88.79% 16 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
55 35
5.33 556.66% 11 May 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
2 6
7 -14.29% 10 May 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
5 5
0.84 495.24% 4 May 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
300 325
303.68 7.02% 13 May 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 20
1.16 1624.14% 14 Apr 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
6 6
2 200% 7 Mar 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
5 5
3.44 45.35% 12 Mar 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
3 3
2.87 -12.89% 6 Mar 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
4 4
1.78 124.72% 14 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
10 8
0.8 900% 10 Nov 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
7 6
n/a n/a 6 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
7 5
n/a n/a 2 May 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 5 Feb 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
9
n/a n/a 6 Aug 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Sell
8 6
10.57 -43.24% 7 Aug 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
8
n/a n/a 5 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
50
n/a n/a 4 Nov 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 20
0.5 3900% 4 Nov 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
65 55
6.41 758.03% 10 Nov 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
175 125
n/a n/a 4 Nov 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 5 Oct 17, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
2 10
10.28 -2.72% 5 Aug 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Jun 27, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
3 2
n/a n/a 4 Apr 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
28 39
n/a n/a 4 Dec 9, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
100 88
9.5 821.05% 2 Sep 20, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
1 13
0.85 1429.41% 3 Feb 9, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 1 Nov 3, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
155 40
3.08 1198.7% 2 Jun 30, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Terminates Coverage On: Buy
3 0
n/a n/a 3 May 5, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
65 70
n/a n/a 2 Mar 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
22500
n/a n/a 1 Jun 2, 2017